Atrium Therapeutics, Inc. Common Stock (RNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has a cash flow conversion efficiency ratio of -0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.25 Million) by net assets ($207.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Atrium Therapeutics, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Atrium Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Atrium Therapeutics, Inc. Common Stock (RNA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Atrium Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Camuzzi Gas Pampeana SA
BA:CGPA2
|
0.030x |
|
Eagle Bancorp Montana Inc
NASDAQ:EBMT
|
-0.024x |
|
Shangri La Hotels Malaysia Bhd
KLSE:5517
|
0.052x |
|
Castles Technology Co Ltd
TW:5258
|
0.095x |
|
Mediwound Ltd
NASDAQ:MDWD
|
-0.044x |
|
Hostelworld Group PLC
IR:HSW
|
0.076x |
|
Creative Sensor Inc
TW:8249
|
0.036x |
|
Reach Subsea
OL:REACH
|
0.131x |
Annual Cash Flow Conversion Efficiency for Atrium Therapeutics, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see RNA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $207.29 Million | $-41.13 Million | -0.198x | +6.03% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more